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Testosterone and gonadotropins but not
SHBG vary with CKD stages in young and
middle aged men
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Abstract
Background: The aim of this study was to assess the effects chronic kidney disease (CKD) had on sex hormones
and lipids in a subgroup of men between 18 and 50 years old with CKD 1–5 stage without diabetes and not
treated with hemodialysis.
Methods: Data were collected from 101 men with different CKD stages.
Results: Higher CKD stage (lower function) had a significant negative linear trend on total testosterone level
(p < 0.01) and free testosterone level (p < 0.01), with a significant increase of luteinizing hormone (LH) (p < 0.01), and
prolactin (p < 0.01), while SHBG remained unchanged between the CKD stages. Triglycerides but not total cholesterol,
HDL –cholesterol or LDL-cholesterol increased with higher CKD stage. A negative correlation was observed between
BMI, SHBG and free testosterone (p < 0.01 for both) but not with other sex hormones. Age per se was related
to a significant decrease of total and free testosterone level (p < 0.01 for both) even after correction for BMI.
Decreased levels of total testosterone and estimated free testosterone levels had a significant correlation with
an increased level of triglyceride levels (p <0.01).
Conclusions: Our results indicate that CKD stage per se is a factor affecting testosterone levels in combination with
age in men between 18 and 50 years old with CKD 1–5 stage, not treated with hemodialysis.
With increased CKD stage there was a significant increase in LH level and a pattern of hypergonadotropic
hypogonadism. SHBG remained unchanged between the CKD stages.
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Résumé
Objectifs: Le but de cette étude était d’évaluer les effets d’une maladie rénale chronique (MRC) sur les hormones
sexuelles et les lipides dans une sous-population d’hommes âgés de 18 à 50 ans porteurs d’une MRC de stade 1-5,
non diabétiques et non traités par hémodialyse.
Méthodes: Les données ont été obtenues chez 101 hommes qui présentaient différents stades de MRC.
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Résultats: Un stade plus élevé de MRC (fonction plus réduite) a une tendance linéaire négative sur les taux de
testostérone totale (p<0,01) et de testostérone libre (p<0,01), avec une augmentation significative de la LH (p<0,01)
et de la prolactine (p<0,01), alors que les taux de SHBG ne diffèrent pas entre les stades. Les triglycérides
augmentent avec les stades plus élevés de MRC, ce qui n’est pas le cas du cholestérol total, du cholestérol HDL, ou
du cholestérol LDL. L’IMC est négativement corrélé à la SHBG (p<0,01) et à la testostérone libre (p<0,01), mais n’est
pas corrélé aux autres hormones sexuelles. L’âge per se est lié à une diminution significative des taux de
testostérone totale (p<0,01) et de testostérone libre (p<0,01), corrélation qui persiste après ajustement sur l’IMC. Des
taux diminués de testostérone totale et de testostérone libre estimée sont significativement corrélés à un niveau
augmenté des taux de triglycérides (p<0,01).
Conclusions: Nos résultats indiquent que le stade de la MRC per se est un facteur qui affecte les taux de
testostérone en combinaison avec l’âge chez les hommes de 18 à 50 ans porteurs d’une MRC de stade 1-5 et non
traités par hémodialyse.
L’élévation du stade de MRC est associée à une augmentation significative du taux de LH et à un profil
d’hypogonadisme hypergonadotrophique. La SHBG n’est pas modifiée par le stade de MRC.
Mots-clés: maladie rénale chronique/hypogonadisme/taux de testostérone
Background
Chronic kidney disease (CKD) is found in more than
10 % of the general population [1, 2]. It is well recog-
nized that cardiovascular diseases (CVD) are linked to
CKD [3], and that chronic kidney disease is recognized
as an independent risk factor for premature CVD [3].
The exact role of androgens in the development of car-
diovascular and CKD is still unclear.
In men with type 2 diabetes mellitus suboptimal testos-
terone concentration is a common finding in one-third of
the men along with a normal LH [4]. And presence of
type 2 diabetes and CKD increase the prevalence of
hypogonadism from 5 % to 26 % [4]. Data from meta-
analysis have also shown that men with non-diabetic
CKD have a faster progression to end stage renal disease
(ESRD) compared to female, although other studies did
not identify gender as a risk factor for CKD or for
CKD progression [5, 6]. In men with CKD gonadal
dysfunction with elevation of serum gonadotropin
concentration is a frequent finding, affecting 26–66 %
of men with different stages of CKD [7].
Subfertility is also a common problem in men with
CKD and we have previously shown that CKD stage per se
is a factor determining the number of spermatozoa avail-
able in epididymis for ejaculation. This was in part inde-
pendent of age-related decrease of testosterone level and
BMI in a subgroup of men between 18 and 50 years old
with CKD 1–5 stage, not treated with hemodialysis [8].
Hypergonadotropic hypogonadism is a well established
hormonal derangement associated with CKD [9]. In a popu-
lation free from renal disease, testosterone deficiency is sug-
gested to take part in the atherosclerotic process. Emerging
evidence indicates that androgens may provide a protective
effect against the development and/or progression of athero-
sclerosis in men [10]. Hypogonadism in men with CKD not
yet on dialysis, has been associated with arterial stiffness and
endothelial dysfunction [11] supporting the theory that
hypogonadism could be a key link with CVD in this group
of men [12]. However it cannot be excluded that the athero-
sclerotic process significantly increases as a consequence of
progression of the kidney disease (e.g. low testosterone levels
in CKD may therefore be an adaptive mechanism during
progression) rather than as a consequence of low testoster-
one level per se [13].
It is also possible that prescribed medications to pa-
tients with CKD could interfere directly with synthesis
of sex hormones e.g. statins, angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin II receptor
blockers (ARBs) [7, 14, 15]. Several expert groups have
presented guidelines for the diagnosis of testosterone
deficiency [16, 17]. Those guidelines recommend that
the diagnosis of hypogonadism should only be made in
men with characteristic symptoms or signs of testoster-
one deficiency in combination with a documented low
serum testosterone level.
The most widely accepted parameters to establish
the presence of hypogonadism is the measurement of
total serum testosterone. There are no generally ac-
cepted lower limits of normal total testosterone levels.
There is, however, general agreement that patients
with a total serum testosterone level above 12nmol/L
generally do not benefit from treatment [17].
Most studies of sex hormones in men with CKD
have been focused on patients with end stage renal
disease (CKD 5 without dialysis) and on patients on
hemodialysis, and there is little information about sex
hormone level development and serum lipid profiles
throughout the different CKD stages. This study ana-
lyzes aspects of sex hormone levels and lipids, among
a subgroup of Swedish men between 18–50 years old
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Patients with different CKD stages aged 18–50 years
from the Department of Nephrology, Karolinska Uni-
versity Hospital, Stockholm, Sweden were recruited
from December 2012 to December 2013 and divided
into five groups according to their stage of renal im-
pairment (CKD 1-CKD 5). Staging of CKD was defined
according to the presence or absence of kidney damage
and level of kidney function, irrespective of type of
kidney diagnosis [18], according to Table 1. The CKD
stage was based on Creatinine–Cystatin C Equation)
for Estimating Glomerular Filtration Rate (eGFR) [19].
Of the 145 men invited 101 fulfilled inclusion criteria
and volunteered to provide fasting blood samples. In
Tables 2 and 3 characteristics of the participants are in-
cluded. Participants were not included if they were
smokers or former smokers (>3 months), had type 1 or
type 2 diabetes mellitus, had a previous renal trans-
plantation, or were treated with testosterone replacement
therapy. Patients with diabetes mellitus were excluded
because both forms of diabetes may be associated with
hypercholesterolemia and hypertriglyceridemia at hyper-
glycemia [20].
All participants gave written and oral informed con-
sent to participate, and the study was approved by the
Ethics Committee of Karolinska Institute.
Assays
All samples were taken in morning (07.00-09.00 a.m.)
after an overnight fast (12 hrs).
Total testosterone level was measured with a chemilu-
minescent immunoassay for quantitative determination of
total testosterone level in human serum and plasma using
the Access Imunoassay System (Beckman Coulter). The
intra-assay and inter-assay coefficients of variation for
testosterone were less than 5.0 %. Free serum testosterone
was calculated by the method of Vermeulen [21].
LH and FSH were determined with an AutoDELFIA
hLH assay (PerkinElmer Life and Analytical Sciences,
Turku, Finland) two-site immunoradiometric assay. The
intra-assay and inter-assay coefficients of variation were
1.9 and 2.2 % respectively for LH and 2.2 and 3.5 % for
FSH. SHBG and prolactin were measured with a paramag-
netic particle chemiluminescent immunoassay (Access
SHBG assay UniCel DxI 800, Beckman Coulter, Inc,
USA). The intra-assay and inter-assay coefficients of vari-
ation for SHBG were 4.0 and 5. 5 % respectively, and
for prolactin 3.5 and 5.0 %. Plasma glucose concentra-
tion was measured by a glucose oxydase method (Glu-
kos HK, Modular P, Roche Diagnostics, Indianapolis,
IN). The intra-assay and inter-assay coefficients of vari-
ation for glucose were 1.2 and 1.9 % respectively.
Total cholesterol, High-density lipoprotein (HDL)-
cholesterol, Low-density lipoprotein (LDL) – choles-
terol, creatinine and cystatin C were measured by the
routine chemistry accredited laboratory at the Karolinska
University Hospital (Modular P, Roche Diagnostics,
Mannheim). LDL-cholesterol was calculated according to
the Friedewald formula [22]. All participants had
plasma triglycerides < 4.5 mmol /L (the upper limit for
estimates with the formula). Reference range for
healthy men between 18–50 years of age is included in
the Additional file 1: Table S1.
Statistical analysis
All data shown are expressed as means ± SD. The
normality was tested with a probability plot and the
Kolmogorov-Smirnov one-sample test. Log transformed
values were used for prolactin, SHBG and triglycerides
levels in the analysis and then back transformed for data
presentation. One way Analysis of Variance (ANOVA)
was used to test the differences between CKD stages
for age, BMI, Hemoglobin, creatinine, eGFR, sex hor-
mones and lipids. A Spearman´s rank test was used
to determine univariate correlations between variables.
Multiple linear regression analyses were performed
with BMI and age as covariates. Data were considered
statistically significant at p < 0. 05.
Statistical analyses were performed using Statistica,
Statsoft version 10.0 (Tulsa, OK, USA).
Results
Clinical characteristics
The clinical characteristics of the 101 men who were in-
cluded and had accepted to participate in the study are
shown in Tables 2 and 3. The group of men enrolled in
this study did not differ significantly in age or BMI
between the different five CKD stages.
Table 1 Stages of chronic kidney disease (CKD) was defined
according to the presence or absence of kidney damage and
level of kidney function, irrespective of the type of kidney
disease (diagnos) [43]
Stage Description GFR (ml/min per 1.73 m2)
1 Kidney damage with
normal or increased GFR
≥90
2 Kidney damage with
mild decreased GFR
60 to 89
3 Moderate decreased GFR 30 to 59
4 Severe decreased GFR 15 to 29
5 Kidney failure <15 or dialysis
GFR values are normalized to an average surface area of 1.73 m2
Hylander and Lehtihet Basic and Clinical Andrology  (2015) 25:9 Page 3 of 7
Sex hormone level in serum
There was a significant decrease in total testosterone
level and estimated free testosterone with CKD stages,
p <0.01 for trend for both. LH and prolactin levels in-
creased significantly, p <0.01. FSH showed a tendency
to increase, although not significantly. No significant
differences were observed for SHBG levels among the
different CKD stages, Table 4.
Serum lipid profile
In men with CKD stage 1–5 a significant increase in
triglycerides levels was seen with increased CKD stage,
p < 0.01. No significant differences were observed for
total cholesterol, HDL-cholesterol or LDL-cholesterol
levels among the different CKD stages, Table 4.
Relationships between testosterone and lipids
The effect of decreased total testosterone levels on lipid
parameters had a significant correlation with level of
triglycerides (r = − 0. 42, p <0.001) and HDL –choles-
terol (r =0.25, p = 0.01), Table 5. A decrease although
not significant was also seen for total cholesterol level
but not for LDL-cholesterol, Table 5. Free testosterone
correlated with level of triglycerides but not with HDL-
cholesterol. A borderline significant decrease was seen
for total cholesterol, Table 5.
Effect of BMI and age on sex hormones
In this study BMI had no significant correlation with
total testosterone, LH, FSH or prolactin. A significant
correlation with free testosterone was observed, Table 5.
There was a negative significant correlation with SHBG
(p < 0.01), Table 5. This significant correlation persisted
after correction for age. Age was correlated to a de-
crease in total testosterone level and free testosterone
level (p < 0.01) even after correction for BMI.
Discussion
The association of different stages of CKD with sex
hormones has been examined in several previous stud-
ies [11, 23]. As far as we know most studies in men
with CKD have been performed in older patients or pa-
tients with end stage renal disease. It has been shown
previously that there is a negative correlation between
endogenous testosterone and CKD stage 1–5 [7, 11].
The mechanism for this is likely to involve, at least in
some part some alteration or derangement of the male
reproductive hormone profile [9]. This supports our
findings of a significant decrease in testosterone level
with increased CKD stages even in younger men and
middle-aged men.
Whether decreased testosterone level is a result of
degradation of uremic metabolites accumulated mainly
in testes and affecting the Leydig cells as a result of
progressive kidney disease or an inhibition of cAMP
production associated with inhibition of 125I-human
chorionic gonadotropin binding of the luteinizing
hormone receptor in Leydig cells [23] is still unknown.
A previous study has supported the theory that chronic
kidney disease mainly affect testes by a defect in 17 ~
−hydroxysteroid dehydrogenase evidenced by a decrease
in testosterone/androstenedione ratio at progressive CKD
and a lack of correction by hCG administration [24].
Table 3 Diagnosis of participants in stage CKD 1–5
Diagnosis CKD 1 CKD 2 CKD 3 CKD 4 CKD 5
N = 101 23 20 27 13 18
Glomerular disease 11 13 15 7 11
Hypertensive nephrosclerosis 2 2 3 1 2
Tubulointerstial disease 2 2 3 1 1
Vascular disease 3 1 1 1 3
Polycystic kidney disease 5 2 5 3 1
Medications
Statins 5 3 14 6 8
ACE inhibitors 11 10 13 8 9
Angiotensin receptor blockers 2 11 9 8 10
Diuretic 0 3 5 6 10
B-blockers 3 4 6 7 10
Calcium channel blockers 4 5 13 6 7
Table 2 Baseline clinical characteristics of participants in stage CKD 1–5
CKD 1 CKD 2 CKD 3 CKD 4 CKD 5 p
N = 101 23 20 27 13 18
Age (year) 34.0 ± 9.1 40.1 ± 6.1 41,7 ± 6,4 42.1 ± 5.95 38.5 ± 8.32 n.s.
BMI (kg/m2) 26.1 ± 5.2 25.9 ± 5.3 25.1 ± 3.6 27.3 ± 5.33 25.2 ± 2.89 n.s.
Hemoglobin (g/L) 149.9 ± 7.2 146.4 ± 9.1 133.8 ± 13.9 121.4 ± 12.1 111.6 ± 13.3 <0.001
Creatinine ( μmol/L) 81.6 ± 11.2 110.7 ± 15.2 153.1 ± 38.9 387 ± 162 633.1 ± 203 <0.001
Cystatin C (mg/L) 4.26 ± 0.29 2.44 ± 0.13 1.66 ± 0.12 0.98 ± 0.05 0.84 ± 0.05 <0.001
eGFR 92.6 ± 1.5 77.1 ± 9.5 47.9 ± 10.0 21.1 ± 5.4 12.1 ± 2.0 <0.001
CKD staging was tested with one way ANOVA. Data were considered statistically significant at P < 0.05CKD stage was based on Creatinine–Cystatin C Equation) for
Estimating GFR (eGFR) [19]
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With higher CKD stages there was a significant in-
crease in the LH level and the development of a pattern
of hypergonadotropic hypogonadism, which indicates
that uremic metabolites secondary to the increased
CKD stage affect testes more than the hypothalamic or
pituitary function. Alternatively the degradation of uremic
metabolites in the hypothalamic or pituitary region is fas-
ter and more pronounced than in testes. Previous studies
have shown that hemodialysis does not improve the func-
tion of the HPT axis [25] but that renal transplantation
may reverse the uremic damage to testicular function,
suggesting that clearance of uremic metabolites is insuffi-
cient on hemodialysis treatment.
A novel finding was that SHBG level was unchanged
between CKD stages, supporting the theory that also
bioavailable testosterone decreases with CKD staging.
The unchanged SHBG level does not support previ-
ous finding that estradiol level increases in men with
CKD [26]. A high concomitant estradiol level is a
common finding in men with CKD and gives a con-
comitant increase of SHBG level [26, 27]. However
we cannot exclude that estradiol levels increase with
CKD stages and then compensate the effect of de-
creasing testosterone on SHBG levels. The
discrepancy between our results and previous studies
could in part be explained by exclusion of patients
with diabetes mellitus included in this study, and also
that there were no patients with high BMI included,
thus the metabolic impact could be minor in our
study.
Of additional interest is insulin even among CKD pa-
tients without manifest or overt diabetes mellitus.
Clearance of insulin is reduced with progressive CKD
stage [28] and insulin resistance appears at an earlier
stage of CKD [28] . Induction of insulin resistance in
podocytes leads to glomerulosclerosis in animal models
and development of CKD in observational human stud-
ies [29]. Elevated insulin level also produces a decrease
in the hepatic production of SHBG [30] which in part
can explain our results.
SHBG is also down regulated by proinflammatory
cytokines that are associated with the prevalence and
severity of CKD [31]. And SHBG levels can therefore
represent a sensitive indicator of low-grade inflammation.
Hyperprolactinemia has been shown to affect at least
30 % of patients with CKD [32] and is the consequence
of both reduced renal clearance [33] and increased pro-
duction [34]. Prolactin might influence the metabolism
of SHBG [35] by its inhibiting hormonal influences and
decrease of SHBG in hyperprolactinemia [35]. In our
study and a previous study of men without renal dis-
eases [36] there was no correlation between SHBG and
prolactin, but that does not exclude a correlation at a
higher threshold level.
Hyperprolactinemia in CKD may be a contributing
factor in the atherosclerotic process [37]. Increased
expression of prolactin receptors has been found in
human atherosclerotic plaques [38] and may be con-
tributing factor to vascular derangements per se [37].
Table 5 Multiple linear regression analyses were performed
with BMI and age as covariates
Total testosterone Free testosterone
Spearman R P-value Spearman R P-value
Cholesterol −0.19 0.053 −0.19 0.05
HDL-cholesterol 0.25 0.01 0.10 0.27
LDL-cholesterol −0.06 0.55 −0.16 0.09
Triglycerides −0.42 0.001 −0.23 0.02
Data were considered statistically significant at P < 0. 05
Table 4 Comparison of the levels of sex hormones and lipid levels in serum in participants in stage CKD 1–5
CKD 1 CKD 2 CKD 3 CKD 4 CKD 5 p
N = 101 23 20 27 13 18
S- Testosterone (nmol/L) 14.89 ± 3.91 14.10 ± 4.15 13.22 ± 3.81 10.81 ± 4.53 8.82 ± 3.81 <0.01
S-SHBG (nmol/L) 29.56 ± 12.73 35.50 ± 13.03 34.55 ± 13.51 33.07 ± 12.9 28.55 ± 13.47 ns
Free testosterone nmol/L 0.33 ± 0.10 0.28 ± 0.06 0.25 ± 0.05 0.19 ± 0.07 0.19 ± 0.08 <0.01
S-LH (U/L) 4.16 ± 2.07 3.33 ± 1.40 6.77 ± 4.22 6.50 ± 2.71 9.43 ± 7.60 <0.01
S-FSH (U/L) 3.67 ± 2.65 3.67 ± 2.06 6.85 ± 4.04 5.21 ± 4.82 13.51 ± 6.98 ns
S-Prolactin (μg/L) 7.76 ± 2.04 8.54 ± 3.36 9.24 ± 2.47 16.50 ± 12.54 17.41 ± 2.13 <0.01
S-Cholesterol (mmol/L) 5.04 ± 1.14 5.03 ± 1.65 4.85 ± 1.06 4.72 ± 0.72 5.20 ± 1.30 n.s.
S-HDL (mmol/L) 1.20 ± 0.31 1.25 ± 0.24 1.2 ± 0.29 1.09 ± 0.24 1.24 ± 0.48 n.s.
S-LDL (mmol/L) 2.98 ± 0.99 3.34 ± 1.08 3.02 ± 0.97 2.70 ± 0.71 3.03 ± 1.21 n.s.
S-Tg (mmol/L) 1.65 ± 1.12 1.17 ± 0.66 1.33 ± 0.68 2.17 ± 1.43 2.61 ± 1.52 <0.01
S-glucose (mmol/L) 5.13 ± 0.59 5.07 ± 0.45 5.18 ± 0.67 4.80 ± 0.67 5.18 ± 0.62 n.s.
Values reported are mean ± SD. Linear trend between sex hormones and CKD staging was tested with one way ANOVA. Data were considered statistically
significant at P < 0.05. The conversion factor for prolactin from mass to units is 21.2. ((μg/L) x 21.2 =mIU/L)
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The lack of significant changes in SHBG levels among
the participants in our study could be multifactorial
due to medications, lifestyle comorbidity and dietary
factors [16, 39]. With nephrotic syndrome as a condi-
tion associated with alternations in SHBG concentra-
tion [16].
In the present study there was a significant negative
correlation with triglyceride levels and CKD stages.
Furthermore decreased testosterone levels were seen in
more severe CKD stages with more than 58 percent in-
crease of triglycerides in CKD stage 5 compared with
CKD 1 stage. It has previously been shown that a
higher triglyceride level contributes to a more rapid de-
cline in renal function in a non-diabetic patient cohort
with CKD [40].
In a previous study by Gungor et al. [41] a negative
correlation was seen between total cholesterol, trigly-
ceride and testosterone levels in the cases on the
chronic hemodialysis schedule. It is likely that we
could not find a significant correlation between CKD
staging and total cholesterol due to the small number
of participants and high number of patients using
antihyperlipidemic agents.
Our study has several limitations. Firstly, this was a
cross-section observational study performed in a small
cohort of patients with different diagnoses and CKD
stages, and different medical treatment including statins,
Table 2. Although the most prominent effects attribut-
able to statin therapy are the potent LDL-cholesterol
lowering properties, it is also well established that statins
significantly reduce triglycerides [42]. It can therefore
not be excluded that some of the difference observed
could be related to statin treatment. However statin
treatment among patients was more common with in-
creased CKD staging, Table 2.
There was a negative correlation between age and
decreased testosterone level and also between triglyc-
erides and the testosterone level. No correlation was
seen with BMI and sex hormones, except a negative
correlation with SHBG. This might be explained by
the limited number of participants and lack of over-
weight and obese participants included.
Conclusions
CKD stage per se is a factor determining testosterone
level together with age. A decreased testosterone level is
also correlated with an increased level of triglycerides
but not with cholesterol SHBG remained unchanged be-
tween the CKD stages.. With an increased CKD stage
there was a significant increase in LH level, which indi-
cates that uremic metabolites secondary to increased
CKD stage in men between 18 and 50 years old with
CKD 1–5 stage, not treated with hemodialysis affect tes-
tes more than the hypothalamic or pituitary function.
Additional file
Additional file 1: Table S1. A summary of the reference range for
healthy men between 18–50 years of age. The conversion factor for
prolactin from mass to units is 21.2. ((μg/L) x 21.2 = mIU/L). (DOC 33 kb)
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